febuxostat has been researched along with Asymptomatic Conditions in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Eguchi, K; Higashi, Y; Ishibashi, R; Ishizaka, N; Ishizu, T; Kanzaki, Y; Kario, K; Kato, T; Maemura, K; Murohara, T; Node, K; Ohishi, M; Oyama, JI; Sata, M; Sezai, A; Taguchi, I; Tanaka, A; Teragawa, H; Tomiyama, H; Toyoda, S; Ueda, S; Yamada, H; Yokote, K | 1 |
| Gu, J; Lin, H; Pan, JA; Wang, CQ; Zhang, JF | 1 |
| Chang, WC; Chen, TC; Hsu, FS; Hwang, JJ; Lee, CC; Liu, CW; Lo, C; Shau, WY; Wang, ML | 1 |
| Chatterjee, S; Golay, V; Pandey, R; Raychaudhury, A; Sircar, D; Waikhom, R | 1 |
| Cheetham, TC; Levy, G | 1 |
| Dalbeth, N; Stamp, L | 1 |
2 review(s) available for febuxostat and Asymptomatic Conditions
| Article | Year |
|---|---|
The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
Topics: Aged; Allopurinol; Asymptomatic Diseases; Biomarkers; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2019 |
Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution.
Topics: Allopurinol; Asymptomatic Diseases; Drug Eruptions; Drug Hypersensitivity; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Probenecid; Uricosuric Agents; Urolithiasis | 2017 |
2 trial(s) available for febuxostat and Asymptomatic Conditions
| Article | Year |
|---|---|
Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
Topics: Aged; Aged, 80 and over; Asymptomatic Diseases; Carotid Artery Diseases; Carotid Intima-Media Thickness; Disease Progression; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Prospective Studies; Single-Blind Method; Uric Acid | 2020 |
Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.
Topics: Adult; Aged; Asymptomatic Diseases; Double-Blind Method; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; India; Male; Middle Aged; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome | 2015 |
2 other study(ies) available for febuxostat and Asymptomatic Conditions
| Article | Year |
|---|---|
Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia.
Topics: Aged; Asymptomatic Diseases; Biomarkers; Blood Pressure; Databases, Factual; Diastole; Disease Progression; Drug Prescriptions; Febuxostat; Female; Gout Suppressants; Heart Disease Risk Factors; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Hyperuricemia; Male; Middle Aged; Protective Factors; Retrospective Studies; Risk Assessment; Stroke Volume; Time Factors; Uric Acid; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2020 |
Is It Time to Start Treating Asymptomatic Hyperuricemia?
Topics: Asymptomatic Diseases; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Male; Renal Insufficiency, Chronic | 2015 |